1. Green tea polyphenol epigallocatechin-3-gallate ameliorates insulin resistance in non-alcoholic fatty liver disease mice
- Author
-
Fei Zou, Jin-qiang Guo, Xiao-cui Lu, Zijun Meng, Hua Li, Bing-de Luo, Yan-ping Deng, Zhi-wei Zheng, Lu Gan, and Ri-bo Xiong
- Subjects
Blood Glucose ,Male ,medicine.medical_specialty ,Time Factors ,medicine.medical_treatment ,Diet, High-Fat ,Insulysin ,Camellia sinensis ,Catechin ,Insulin resistance ,Downregulation and upregulation ,Non-alcoholic Fatty Liver Disease ,Internal medicine ,Hyperlipidemia ,medicine ,Hyperinsulinemia ,Animals ,Hypoglycemic Agents ,Insulin ,Pharmacology (medical) ,Pharmacology ,Plants, Medicinal ,Dose-Response Relationship, Drug ,Traditional medicine ,business.industry ,Pancreatic islets ,Fatty liver ,food and beverages ,nutritional and metabolic diseases ,General Medicine ,medicine.disease ,Mice, Inbred C57BL ,Disease Models, Animal ,Endocrinology ,medicine.anatomical_structure ,Liver ,Original Article ,Insulin Resistance ,Steatosis ,business ,Biomarkers ,Phytotherapy - Abstract
Epigallocatechin-3-gallate (EGCG) is a major polyphenol in green tea. In this study, we investigated the effects of EGCG on insulin resistance and insulin clearance in non-alcoholic fatty liver disease (NAFLD) mice.Mice were fed on a high-fat diet for 24 weeks. During the last 4 weeks, the mice were injected with EGCG (10, 20 and 40 mg·kg(-1)·d(-1), ip). Glucose tolerance, insulin tolerance and insulin clearance were assessed. After the mice were euthanized, blood samples and tissue specimens were collected. Glucose-stimulated insulin secretion was examined in isolated pancreatic islets. The progression of NAFLD was evaluated histologically and by measuring lipid contents. Insulin-degrading enzyme (IDE) protein expression and enzyme activity were detected using Western blot and immunocapture activity assays, respectively.The high-fat diet significantly increased the body weight and induced grade 2 or 3 liver fatty degeneration (steatosis, lobular inflammation and ballooning) accompanied by severe hyperlipidemia, hyperglycemia, hyperinsulinemia and insulin resistance in the model mice. Administration of EGCG dose-dependently ameliorated the hepatic morphology and function, reduced the body weight, and alleviated hyperlipidemia, hyperglycemia, hyperinsulinemia and insulin resistance in NAFLD mice. Furthermore, EGCG dose-dependently enhanced insulin clearance and upregulated IDE protein expression and enzyme activity in the liver of NAFLD mice.EGCG dose-dependently improves insulin resistance in NAFLD mice not only by reducing body weight but also through enhancing the insulin clearance by hepatic IDE. The results suggest that IDE be a potential drug target for the treatment of NAFLD.
- Published
- 2015
- Full Text
- View/download PDF